ClinicalTrials.gg
CompletedNCT00446043Updated Jul 11, 2023Results posted

Long-term Study of Efficacy/Safety of Adapalene/Benzoyl Peroxide Topical Gel in Acne Vulgaris Subjects

A Phase 3 interventional study of Adapalene/Benzoyl Peroxide in Acne Vulgaris, sponsored by Galderma R&D. Completed at 1 site in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2023-07-11.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years after the study started (first participant enrolled Feb 2004, registered Mar 2007).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
452
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing adapalene in Acne Vulgaris — none open to participants now, 2 under way, none of them phase 3. Adapalene · Acne Vulgaris.

Enrollment
11th of 30
452 · median 215
Started
2004
with 1 other
Phase 3
9 of 30
none open now
Registered
4th of 30
by date
Lead sponsor
10 of 30
Galderma R&D

Among the 30 studies testing adapalene in Acne Vulgaris, this one is the 11th largest by enrollment, is one of 2 that started in 2004, is one of 9 in phase 3, and was the 4th registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

None of the 30 studies testing adapalene in Acne Vulgaris is open now. The open studies under Acne Vulgaris, anywhere →

About adapalene

Adapalene: first FDA approval 1996 (DIFFERIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 30 studies testing adapalene in Acne Vulgaris as a file.
02

Study summary

This was a multi-center, open-label, non-comparative study that evaluated the long-term safety and efficacy profile of Adapalene/Benzoyl Peroxide Gel.

Subjects were evaluated at Baseline, Weeks 1 and 2, and Months 1, 2, 4, 6, 8, 10, and 12.

Safety was evaluated by spontaneous reports of Adverse Events (AEs), the Local Tolerability Assessment (Erythema, Scaling, Dryness, and Stinging/Burning), routine laboratory testing (hematology, blood chemistry, and urinalysis), and monitoring of suspected sensitizations. Efficacy was evaluated by analysis of Percent Change from Baseline in Inflammatory, Noninflammatory, and Total Lesion Counts, and by the Subject's Assessment of Acne.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

Keywords

  • Acne Vulgaris
  • Adapalene
  • Benzoyl Peroxide
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A clinical diagnosis of acne vulgaris with facial involvement.
  • A minimum of 20 but not more than 50 Inflammatory lesions.
  • A minimum of 30 but not more than 100 Noninflammatory lesions.

Exclusion criteria

Exclusion Criteria:

  • Subjects with presence of nodules or cysts.
  • Acne conglobate, acne fulminans, secondary acne, or severe acne.
  • Underlying diseases that required the use of interfering topical or systemic therapy.
  • Use of prohibited medications prior to the study unless appropriate was documented.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
452 participants (actual)

Study arms

  • Experimental
    Adapalene/Benzoyl Peroxide

    Participants were treated with adapalene 0.1 percent (%) \[weight by weight (W/W)\] and benzoyl peroxide 2.5 percent (%) (W/W) gel topically to the face and trunk area once daily in the evening.

    Drug: Adapalene/Benzoyl Peroxide

Interventions

  • DrugAdapalene/Benzoyl Peroxide

    Drug pages: Adapalene · Benzoyl Peroxide

    Adapalene 0.1 percent (%) \[weight by weight (W/W)\] and benzoyl peroxide 2.5 % (W/W) gel topically daily in the evening.

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Inflammatory, Noninflammatory and Total Lesion Count at Month 12 LOCF

    Percent change in inflammatory, noninflammatory and total lesions at Month 12 was measured from baseline lesions. The noninflammatory lesion count was the sum of open comedones (a mass of sebaceous material that is impacted behind an open follicular orifice (blackhead) and closed comedones (a mass of sebaceous material that is impacted behind a closed follicular orifice (whitehead). The inflammatory lesion count was the sum of papules (a small, solid elevation less than 1.0 cm in diameter) and pustules (a small, circumscribed elevation of the skin that contains yellow-white exudate). The total lesion count was the sum of inflammatory and noninflammatory lesions. Missing adapalene and benzoyl peroxide data were imputed using last observation carried forward (LOCF).

    Time frame: Baseline, Month 12 LOCF

  2. Number of Participants Categorized Based on Participant's Assessment Scale of Acne at Month 6

    Participant's assessment of acne improvement was graded as 0; complete improvement, 1; marked improvement, 2; moderate improvement, 3; minimal improvement, 4; no change, 5; worse.

    Time frame: At Month 6

  3. Number of Participants Categorized Based on Participant's Assessment Scale of Acne at Month 12

    Participant's assessment of acne improvement was graded as 0; complete improvement, 1; marked improvement, 2; moderate improvement, 3; minimal improvement, 4; no change, 5; worse.

    Time frame: At Month 12

Secondary outcomes

  1. Number of Participants With Local Tolerability Assessment For Erythema

    Local tolerability assessment for erythema (abnormal redness of the skin) was graded on a "0" (none) to "3" (severe) scale as follows; none (0- no erythema), mild (1- slight pinkness present), moderate (2- definite redness, easily recognized), severe (3- intense redness). The worst severity scores were generally mild or moderate, and rarely severe.

    Time frame: Baseline, Weeks 1 and 2, Months 1, 2, 4, 6, 8, 10 and 12

  2. Number of Participants With Local Tolerability Assessment For Scaling

    Local tolerability assessment for scaling (abnormal shedding of the stratum corneum) was graded on a "0" (none) to "3" (severe) scale as follow; none (0- no Scaling), mild (1- barely perceptible shedding, noticeable only on light scratching or rubbing), moderate (2- obvious but not profuse shedding), severe (3- heavy scale production).

    Time frame: Baseline, Weeks 1 and 2, Months 1, 2, 4, 6, 8, 10 and 12

  3. Number of Participants With Local Tolerability Assessment For Dryness

    Local tolerability assessment for dryness (brittle and/or tight sensation) was graded on a "0" (none) to "3" (severe) scale as follows; none (0- no dryness), mild (1- slight but definite roughness), moderate (2 -moderate roughness), severe (3- marked roughness).

    Time frame: Baseline, Weeks 1 and 2, Months 1, 2, 4, 6, 8, 10 and 12

  4. Number of Participants With Local Tolerability Assessment For Stinging/Burning

    Local tolerability assessment for stinging/burning \[prickling pain sensation immediately after (within 5 minutes of) dosing\] was graded on a "0" (none) to "3" (severe) scale as follows; none (0- no stinging/ burning), mild (1- slight warm, tingling/stinging sensation; not really bothersome), moderate (2- definite warm, tingling/stinging sensation that is somewhat), severe (3- hot, tingling/stinging sensation that has caused definite discomfort).

    Time frame: Baseline, Weeks 1 and 2, Months 1, 2, 4, 6, 8, 10 and 12

  5. Number of Participant With Adverse Event (AE) and Serious Adverse Event (SAE)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

    Time frame: Baseline up to Month 14

  6. Number of Participants With Clinically Significant Abnormal Laboratory Parameters

    Clinical laboratory parameters included hematology, blood chemistry, urinalysis. Number of participants with clinically significant abnormalities in laboratory parameters which were deemed clinically significant by the investigator were reported.

    Time frame: Baseline up to Month 14

07

Results

Posted Jul 11, 2023

Participant flow

A total of 452 participants were enrolled at 28 study centers in the United States from 17 February 2004 to 23 May 2005.

Participant flow — Overall Study
MilestoneAdapalene/Benzoyl Peroxide
Started452
Completed327
Not completed125
Withdrew: Adverse event9
Withdrew: Withdrawal by subject70
Withdrew: Protocol violation2
Withdrew: Lost to follow-up42
Withdrew: Pregnancy2

Outcome measures

PrimaryPercent Change From Baseline in Inflammatory, Noninflammatory and Total Lesion Count at Month 12 LOCF

Percent change in inflammatory, noninflammatory and total lesions at Month 12 was measured from baseline lesions. The noninflammatory lesion count was the sum of open comedones (a mass of sebaceous material that is impacted behind an open follicular orifice (blackhead) and closed comedones (a mass of sebaceous material that is impacted behind a closed follicular orifice (whitehead). The inflammatory lesion count was the sum of papules (a small, solid elevation less than 1.0 cm in diameter) and pustules (a small, circumscribed elevation of the skin that contains yellow-white exudate). The total lesion count was the sum of inflammatory and noninflammatory lesions. Missing adapalene and benzoyl peroxide data were imputed using last observation carried forward (LOCF).

Time frame:
Baseline, Month 12 LOCF
Reported as:
Mean · percent change
Percent Change From Baseline in Inflammatory, Noninflammatory and Total Lesion Count at Month 12 LOCF
percent changeAdapalene/Benzoyl Peroxide
Inflammatory Lesion Counts-59.70 ± 34.268
Noninflammatory Lesion Counts-58.80 ± 33.206
Total Lesion Counts-58.85 ± 29.273
PrimaryNumber of Participants Categorized Based on Participant's Assessment Scale of Acne at Month 6

Participant's assessment of acne improvement was graded as 0; complete improvement, 1; marked improvement, 2; moderate improvement, 3; minimal improvement, 4; no change, 5; worse.

Time frame:
At Month 6
Reported as:
Count of participants · Participants
Number of Participants Categorized Based on Participant's Assessment Scale of Acne at Month 6
ParticipantsAdapalene/Benzoyl Peroxide
0=Complete Improvement17
1=Marked Improvement149
2=Moderate Improvement147
3=Minimal Improvement31
4=No Change11
5=Worse4
PrimaryNumber of Participants Categorized Based on Participant's Assessment Scale of Acne at Month 12

Participant's assessment of acne improvement was graded as 0; complete improvement, 1; marked improvement, 2; moderate improvement, 3; minimal improvement, 4; no change, 5; worse.

Time frame:
At Month 12
Reported as:
Count of participants · Participants
Number of Participants Categorized Based on Participant's Assessment Scale of Acne at Month 12
ParticipantsAdapalene/Benzoyl Peroxide
0=Complete Improvement40
1=Marked Improvement164
2=Moderate Improvement77
3=Minimal Improvement37
4=No Change6
5=Worse3
SecondaryNumber of Participants With Local Tolerability Assessment For Erythema

Local tolerability assessment for erythema (abnormal redness of the skin) was graded on a "0" (none) to "3" (severe) scale as follows; none (0- no erythema), mild (1- slight pinkness present), moderate (2- definite redness, easily recognized), severe (3- intense redness). The worst severity scores were generally mild or moderate, and rarely severe.

Time frame:
Baseline, Weeks 1 and 2, Months 1, 2, 4, 6, 8, 10 and 12
Reported as:
Count of participants · Participants
Number of Participants With Local Tolerability Assessment For Erythema
ParticipantsAdapalene/Benzoyl Peroxide
Baseline — 0 = None348
Baseline — 1 = Mild94
Baseline — 2=Moderate10
Baseline — 3=Severe0
Week 1 — 0 = None233
Week 1 — 1 = Mild157
Week 1 — 2=Moderate32
Week 1 — 3=Severe1
Week 2 — 0 = None277
Week 2 — 1 = Mild133
Week 2 — 2=Moderate17
Week 2 — 3=Severe2
Month 1 — 0 = None292
Month 1 — 1 = Mild105
Month 1 — 2=Moderate18
Month 1 — 3=Severe0
Month 2 — 0 = None320
Month 2 — 1 = Mild90
Month 2 — 2=Moderate16
Month 2 — 3=Severe0
Month 4 — 0 = None334
Month 4 — 1 = Mild48
Month 4 — 2=Moderate7
Month 4 — 3=Severe0
Month 6 — 0 = None296
Month 6 — 1 = Mild59
Month 6 — 2=Moderate6
Month 6 — 3=Severe0
Month 8 — 0 = None276
Month 8 — 1 = Mild57
Month 8 — 2=Moderate8
Month 8 — 3=Severe0
Month 10 — 0 = None270
Month 10 — 1 = Mild56
Month 10 — 2=Moderate3
Month 10 — 3=Severe0
Month 12 — 0 = None284
Month 12 — 1 = Mild39
Month 12 — 2=Moderate4
Month 12 — 3=Severe0
SecondaryNumber of Participants With Local Tolerability Assessment For Scaling

Local tolerability assessment for scaling (abnormal shedding of the stratum corneum) was graded on a "0" (none) to "3" (severe) scale as follow; none (0- no Scaling), mild (1- barely perceptible shedding, noticeable only on light scratching or rubbing), moderate (2- obvious but not profuse shedding), severe (3- heavy scale production).

Time frame:
Baseline, Weeks 1 and 2, Months 1, 2, 4, 6, 8, 10 and 12
Reported as:
Count of participants · Participants
Number of Participants With Local Tolerability Assessment For Scaling
ParticipantsAdapalene/Benzoyl Peroxide
Baseline — 0=None410
Baseline — 1=Mild41
Baseline — 2=Moderate1
Baseline — 3=Severe0
Week 1 — 0=None228
Week 1 — 1=Mild164
Week 1 — 2=Moderate30
Week 1 — 3=Severe1
Week 2 — 0=None284
Week 2 — 1=Mild130
Week 2 — 2=Moderate14
Week 2 — 3=Severe1
Month 1 — 0=None312
Month 1 — 1=Mild93
Month 1 — 2=Moderate10
Month 1 — 3=Severe0
Month 2 — 0=None338
Month 2 — 1=Mild84
Month 2 — 2=Moderate4
Month 2 — 3=Severe0
Month 4 — 0=None351
Month 4 — 1=Mild38
Month 4 — 2=Moderate0
Month 4 — 3=Severe0
Month 6 — 0=None330
Month 6 — 1=Mild28
Month 6 — 2=Moderate3
Month 6 — 3=Severe0
Month 8 — 0=None301
Month 8 — 1=Mild38
Month 8 — 2=Moderate2
Month 8 — 3=Severe0
Month 10 — 0=None294
Month 10 — 1=Mild33
Month 10 — 2=Moderate2
Month 10 — 3=Severe0
Month 12 — 0=None308
Month 12 — 1=Mild19
Month 12 — 2=Moderate0
Month 12 — 3=Severe0
SecondaryNumber of Participants With Local Tolerability Assessment For Dryness

Local tolerability assessment for dryness (brittle and/or tight sensation) was graded on a "0" (none) to "3" (severe) scale as follows; none (0- no dryness), mild (1- slight but definite roughness), moderate (2 -moderate roughness), severe (3- marked roughness).

Time frame:
Baseline, Weeks 1 and 2, Months 1, 2, 4, 6, 8, 10 and 12
Reported as:
Count of participants · Participants
Number of Participants With Local Tolerability Assessment For Dryness
ParticipantsAdapalene/Benzoyl Peroxide
Baseline — 0=None385
Baseline — 1=Mild65
Baseline — 2=Moderate2
Baseline — 3=Severe0
Week 1 — 0=None195
Week 1 — 1=Mild190
Week 1 — 2=Moderate35
Week 1 — 3=Severe3
Week 2 — 0=None264
Week 2 — 1=Mild152
Week 2 — 2=Moderate12
Week 2 — 3=Severe1
Month 1 — 0=None281
Month 1 — 1=Mild121
Month 1 — 2=Moderate12
Month 1 — 3=Severe1
Month 2 — 0=None311
Month 2 — 1=Mild109
Month 2 — 2=Moderate6
Month 2 — 3=Severe0
Month 4 — 0=None337
Month 4 — 1=Mild52
Month 4 — 2=Moderate0
Month 4 — 3=Severe0
Month 6 — 0=None320
Month 6 — 1=Mild37
Month 6 — 2=Moderate4
Month 6 — 3=Severe0
Month 8 — 0=None281
Month 8 — 1=Mild58
Month 8 — 2=Moderate2
Month 8 — 3=Severe0
Month 10 — 0=None278
Month 10 — 1=Mild48
Month 10 — 2=Moderate3
Month 10 — 3=Severe0
Month 12 — 0=None291
Month 12 — 1=Mild36
Month 12 — 2=Moderate0
Month 12 — 3=Severe0
SecondaryNumber of Participants With Local Tolerability Assessment For Stinging/Burning

Local tolerability assessment for stinging/burning \[prickling pain sensation immediately after (within 5 minutes of) dosing\] was graded on a "0" (none) to "3" (severe) scale as follows; none (0- no stinging/ burning), mild (1- slight warm, tingling/stinging sensation; not really bothersome), moderate (2- definite warm, tingling/stinging sensation that is somewhat), severe (3- hot, tingling/stinging sensation that has caused definite discomfort).

Time frame:
Baseline, Weeks 1 and 2, Months 1, 2, 4, 6, 8, 10 and 12
Reported as:
Count of participants · Participants
Number of Participants With Local Tolerability Assessment For Stinging/Burning
ParticipantsAdapalene/Benzoyl Peroxide
Baseline — 0=None440
Baseline — 1=Mild10
Baseline — 2=Moderate2
Baseline — 3=Severe0
Week 1 — 0=None201
Week 1 — 1=Mild154
Week 1 — 2=Moderate63
Week 1 — 3=Severe5
Week 2 — 0=None319
Week 2 — 1=Mild84
Week 2 — 2=Moderate21
Week 2 — 3=Severe5
Month 1 — 0=None331
Month 1 — 1=Mild66
Month 1 — 2=Moderate14
Month 1 — 3=Severe4
Month 2 — 0=None373
Month 2 — 1=Mild42
Month 2 — 2=Moderate10
Month 2 — 3=Severe1
Month 4 — 0=None364
Month 4 — 1=Mild23
Month 4 — 2=Moderate2
Month 4 — 3=Severe0
Month 6 — 0=None337
Month 6 — 1=Mild20
Month 6 — 2=Moderate4
Month 6 — 3=Severe0
Month 8 — 0=None312
Month 8 — 1=Mild23
Month 8 — 2=Moderate5
Month 8 — 3=Severe1
Month 10 — 0=None303
Month 10 — 1=Mild22
Month 10 — 2=Moderate4
Month 10 — 3=Severe0
Month 12 — 0=None306
Month 12 — 1=Mild19
Month 12 — 2=Moderate1
Month 12 — 3=Severe1
SecondaryNumber of Participant With Adverse Event (AE) and Serious Adverse Event (SAE)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

Time frame:
Baseline up to Month 14
Reported as:
Count of participants · Participants
Number of Participant With Adverse Event (AE) and Serious Adverse Event (SAE)
ParticipantsAdapalene/Benzoyl Peroxide
Participants (N) With At least one AE288
Participants (N) With At Least one SAE5
SecondaryNumber of Participants With Clinically Significant Abnormal Laboratory Parameters

Clinical laboratory parameters included hematology, blood chemistry, urinalysis. Number of participants with clinically significant abnormalities in laboratory parameters which were deemed clinically significant by the investigator were reported.

Time frame:
Baseline up to Month 14
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormal Laboratory Parameters
ParticipantsAdapalene/Benzoyl Peroxide
Hematology0
Blood Chemistry0
Urine Analysis0

Adverse events

Collected over Baseline up to 14 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adapalene/Benzoyl Peroxide0/452 (0%)5/452 (1.1%)288/452 (63.7%)
Most frequent serious events
Most frequent serious events
EventAdapalene/Benzoyl Peroxide
Major DepressionPsychiatric disorders1/452
Bipolar DisorderPsychiatric disorders1/452
Staphylococcal InfectionInfections and infestations1/452
Clavicle FractureInjury, poisoning and procedural complications1/452
SyncopeNervous system disorders1/452
Drug AbuserSocial circumstances1/452
Most frequent other events
Showing 10 of 165
Most frequent other events
EventAdapalene/Benzoyl Peroxide
Dry SkinSkin and subcutaneous tissue disorders80/452
Application Site BurningGeneral disorders64/452
NasopharyngitisInfections and infestations30/452
Upper Respiratory Tract InfectionInfections and infestations26/452
ErythemaSkin and subcutaneous tissue disorders25/452
Skin DesquamationSkin and subcutaneous tissue disorders23/452
SunburnInjury, poisoning and procedural complications21/452
HeadacheNervous system disorders21/452
InfluenzaInfections and infestations18/452
Application Site IrritationGeneral disorders18/452

Baseline characteristics

The intent-to-treat (ITT) population included all participants who were enrolled and to whom medication was dispensed.

Age, Continuous
Age, Continuous(years)Adapalene/Benzoyl Peroxide
Mean18.3 ± 6.62
Sex: Female, Male
Sex: Female, Male(Participants)Adapalene/Benzoyl Peroxide
Female230
Male222
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Adapalene/Benzoyl Peroxide
Race — Caucasian345
Race — Black53
Race — Asian10
Race — Hispanic31
Race — Other13
08

Study locations

1 site
  • Phoebe Rich, MD
    Portland, Oregon 97210, United States
09

References and documents

Publications

  • Leyden JJ. A review of the use of combination therapies for the treatment of acne vulgaris. J Am Acad Dermatol. 2003 Sep;49(3 Suppl):S200-10. doi: 10.1067/s0190-9622(03)01154-x. PubMed 12963896 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2004 to primary completion in May 2005, 15 months.

Results were first posted in Jul 2023, 18 years 1 month after primary completion.

Of 53 industry-sponsored phase 3 interventional studies under Acne Vulgaris, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 17. This study's 15 months is above that.

Counting every sponsor, half of 62 studies reached it within 13 months; a quarter within 10 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2007
First posted
Mar 12, 2007
StartActual
Feb 17, 2004
Primary completionActual
May 23, 2005
CompletionActual
May 23, 2005
Results first posted
Jul 11, 2023
Last update
Jul 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00446043
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
Mar 12, 2007
Start date
Feb 17, 2004
Primary completion
May 23, 2005
Completion
May 23, 2005
Results posted
Jul 11, 2023
Last update
Jul 11, 2023

Study contacts

Michael Graeber, MD
study director · Galderma R&D
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Adapalene · Benzoyl Peroxide

Start the discussion